Torrent Pharma net profit rises 30 percent to Rs 591 crore in Q2

Published On 2025-11-08 11:00 GMT | Update On 2025-11-08 11:00 GMT

Torrent Pharmaceuticals has posted a robust 30 percent jump in its consolidated profit after tax (PAT) at Rs 591 crore for the September quarter, driven by strong sales across key markets. The Ahmedabad-based drugmaker had posted a PAT of Rs 453 crore in the same quarter last year.

According to a regulatory filing, the company’s revenue for the second quarter rose to Rs 3,302 crore, compared to Rs 2,889 crore in the year-ago period.

India revenues stood at Rs 1,820 crores were up by 12% led by outperformance in focus therapies.

In India, Torrent Pharma’s largest market, revenues grew 12% to Rs 1,820 crore, driven by strong performance in its focus therapy areas. The company’s international operations also delivered healthy growth — revenues from Brazil rose 21% to Rs 318 crore, while the US business saw a 26% jump to Rs 337 crore. In Germany, revenues increased 5% to Rs 303 crore during the quarter.

Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores.

It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Torrent Pharma net profit rises 30 percent to Rs 591 crore in Q2

Similar News

Ghaziabad: More than 15.7 lakh vials of banned cough syrup seized, 8 arrested

From Launch to Leadership: Mounjaro Crosses Rs 333 Crore, Becomes India's Top-Selling Drug

Lupin Bioresearch Center gets zero USFDA observation after successful inspection, assessment

JnJ Darzalex faspro approved by USFDA for high risk smoldering multiple myeloma

Alembic Pharma gets USFDA okay for Sumatriptan Injection, Single Dose Autoinjector System

NPPA Fixes Ceiling Prices for 6 Life-Saving Drugs Including Immunoglobulin, Dialysis Fluids, Riboflavin

Torrent Pharma Gets CDSCO Panel Nod to Manufacture, Market Prucalopride Oral Solution